(Reuters) -The U.S. Food and Drug Administration said on Friday that it had eliminated the risk evaluation and mitigation strategies (REMS) for currently approved Bristol-Myers Squibb’s CAR T cell immunotherapies.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Maju Samuel)
